The University of Pittsburgh has lost $42.4 million in research funding from the National Institutes of Health and other government contracts this year as the result of unprecedented budget cuts at the federal agency, employees learned Wednesday.

Pitt’s losses do not include a planned 15% cap on ancillary research costs, which will affect every grant recipient, or a proposed 40% cut to NIH’s 2026 budget, which could further squeeze research dollars.

Pitt spokesman Jared Stonesifer said the funding loss represents 91 terminated awards. That’s an increase from 70 canceled awards valued at $33 million that was tallied a month ago.

Pitt employees and others learned about the losses during a university-wide town hall meeting Wednesday. The disclosure had no immediate impact on spending at Pitt.

Advertise with us

Government and crowdsourced websites show varying funding losses at universities and other research institutions, but the figure released Wednesday was generated by Pitt officials.

“It’s bad,” said Jessica S. Merlin, a physician and professor of medicine at Pitt who was among the researchers to have NIH funding revoked this year. “I don’t know that there’s any nuance here. It’s bad. People are going to lose their jobs. It’s going to impact the economy.”

Dr. Merlin said she was speaking for herself and not the university.

Every $1 in NIH spending translates into $2.50 in economic activity, according to a common metric, so the fallout from fewer research dollars at Pitt is likely to impact the region’s economy.

At the same time, a new study found that Pennsylvania is among the top 10 states in the U.S. hurt by unprecedented cuts to NIH-funded research.

Advertise with us

As of June 4, there were 2,282 NIH grants awarded to U.S. institutions and valued at $3.8 billion that had been terminated and not reinstated, according to the Association of American Medical Colleges, a Washington, D.C.-based educational nonprofit. Pennsylvania’s loss was $81.3 million, among the biggest in the country.

“The impact of funding cuts does not stop at university walls,” AAMC President and CEO David J. Skorton said in a prepared statement Thursday. “When we undermine our research institution, we sacrifice the health and wellbeing of our nation.”

The NIH is the largest public funder of biomedical research in the world, and since President Donald Trump took office in January, the NIH has ended 2,000 research awards totaling about $9.5 billion and $2.6 billion in contracts. The cancellations prompted protest rallies in Pittsburgh by Pitt and Carnegie Mellon University faculty in March and April; a letter of protest to Congress from the Union of Concerned Scientists and 48 scientific societies in March; and most recently, a letter criticizing the cuts and other changes Monday that was signed by more than 300 NIH employees to agency Director Jayanta Bhattacharya.

Some of the letters notifying researchers their grants had been terminated say simply that their research didn’t align with administrative priorities and therefore the funding was being withdrawn. Many of the grants that were revoked addressed diversity, inclusion and equity, LGBTQ and other “woke” issues.

“These actions have resulted in an unprecedented reduction in NIH spending that does not reflect efficiency, but rather a dramatic reduction in life-saving research,” the letter from NIH employees said. “Academic freedom should not be applied selectively based on political ideologies.”

Advertise with us

Separately, Trump’s proposed $2.75 billion or 40% cut to the National Cancer Institute’s 2026 budget has begun drawing blowback from the oncology community. The NCI budget cut was part of a 40% reduction sought for the NIH budget, which would reduce spending to $28 billion from $46 billion this year.

The American Association for Cancer Research, Association for Clinical Oncology and American Society of Hematology are among the cancer groups that have come out against the budget cuts since they were released May 29, which they said could affect cancer research and treatments.

Although he said “it’s obvious that reduced funding can have negative effects,” especially for early career cancer scientists, Ashkan Emadi, chair of medical oncology at the West Virginia University School of Medicine in Morgantown, saw a possible silver lining in the proposed budget reductions.

Less funding could force prioritization of high impact research and streamline collaboration among institutions that share resources, he said. It could also stimulate alternate funding models, including the Department of Defense, Veterans Administration and pharma companies.

“It’s not ideal,” said Dr. Emadi, adding that he was speaking only for himself and not for the university or any political party. “But we’ll persevere.”